Abstract: Therapeutic plasma concentrations of EFV (efavirenz) are between 1,000 ng/mL and 4,000 ng/mL. Concentrations below 1000 ng/mL are associated with higher risk of treatment failure, and concentrations above 4,000 ng/mL are associated with toxicity. The aim of the study was to appreciate EFV plasmas concentrations profile and the association between plasma levels and various characteristics in Beninese patients treated by a 600 mg standard daily-dose. Blood samples were collected and EFV plasma levels were measured by liquid chromatography coupled with mass spectrometry detection in HIV-infected patients receiving EFV in combination with other antiretroviral drugs for at least 14 days. Adverse effects occurring during treatment were collected through a questionnaire. An over-exposure to EFV among Beninese HIV patients were observed, with 46.4% of patients presenting EFV concentration above 4,000 ng/mL, although adverse effects were tolerated indicating that antiretroviral treatment is safe. The measurement of plasma concentration at the steady-state could contribute to early detection of treatment failure and adapt treatment in subjects presenting serious adverse effects within context of therapeutic drug monitoring.
Introduction
 EFV (efavirenz, Fig 1) is a NNRTI (non-nucleoside reverse transcriptase inhibitor) mainly used in combination with others ARV (antiretroviral) agents as first-line HAART (highly active antiretroviral therapy) to control HIV-1 (human immunodeficiency virus) infection in adult, adolescent and child aged of 3 years old and more. Its long half-life (approximately 45 h) facilitates its standard posology of 600 mg by oral route once a day. According to a study performed in a group of 130 HIV-infected patients, average residual plasmatic concentration (Cmin) of the EFV at steady-state is 1,700 +/-1,000 mg/mL [1] . Conclusions The aim o plasma co treatment fa patients. 
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Study Participants
A total of 117 patients were recruited to participate to the descriptive and analytical study depending on the inclusion and non-inclusion criteria. Among them, 5 were excluded for non-observance of the rules (n = 2) and switch of protocol (n = 3) reasons. Thus, statistical analysis was performed on 112 subjects. The characteristics and the therapeutic regimens of the patients are given in Table 1 .
Adverse Effects
Average number of adverse effects per patient was 3.55. The maximum adverse effects presented by patient were 8. Eight percent of the patients did not present any AE. The frequency of adverse effects on the CNS was highest. Dizzinesses are the most dominating. The frequencies of adverse effects observed among patients according to the systems affected are summarized in Table 2 .
Plasmatic Concentrations
EFV plasma concentration average is of 6,360 ± 539 µg/L with a median of 3,925 µg/L. Three patients had concentration below 1,000 ng/mL, since 52 had concentrations above 4000 ng/mL. The distribution and frequencies of all EFV plasma concentrations are summarized in Table 3 .
Plasmatic Concentrations and Demographic, Clinico-Biological, Therapeutic Characteristics
The study determined whether age 
Plasmatic Concentrations and Adverse Effects
Investigating the relationship between plasma concentration and adverse effects, it was observed that the number of adverse effects increased proportionally with plasma concentration (p = 0.04). Thus, an increase of adverse effects number unit induced an increase of 583 µg/mL of plasmatic concentration (IC95 = [33.4; 1132], p < 0.04) (Table 4) . However, the results obtained did not permit to establish an association between plasma concentration and the nature of adverse effects.
Discussion
The aim of the study was to appreciate EFV plasma concentrations profile in HIV infected individuals in Benin, and to explore an association with various factors.
Efavirenz Plasma Concentrations
EFV is a molecule that shows complex pharmacokinetic characteristics resulting in a significant variability of plasma concentrations.
Plasma levels measurement can contribute to better management of HIV infection in clinical practice.
Inter-individual variance of plasma concentrations observed in our study is in the same range, even lower compared with other studies. However, plasma concentration median in our study population was higher than all others studies conducted in Africa, which is very close to that found by Gounden et al. (3, 980 µg/L) in South Africa [12] . But the median observed in our study was strangely higher than those found by Sarfo et al. (1,087 µg/L) or Gunda et al. (2, 112 µg/L) respectively in Ghana and Tanzania [13] [14] . Plasma concentration average of our population was 6,360 µg/L ± 539 µg/L. It is definitely higher than those found by Poeta and Wyen, which were respectively 2,200 and 2,077µg/L [15] [16] . In the studies preceding ours, plasma concentrations averages were included in the therapeutic index described [1,000-4,000 µg/L]. The average observed in our study was above this therapeutic index, meaning that the percentage of patients having a supra-therapeutic plasma concentration is significantly elevated, comparatively with other studies. Indeed, EFV concentrations distribution according to therapeutic interval of our study are significantly different from the distribution observed in various studies (p < 0. 05) [1, 3, [12] [13] [14] .
EFV plasma concentrations distribution according to the therapeutic interval observed in our study is very close to that found by Gounden among South African patients [12] .
Plasma Concentrations and Socio-demographic Factors
Our data did not highlight a relationship between plasma levels and socio-demographic factors such as age, weight, sex, BMI (R 2 = 0.0702). In the same way, Gounden et al. [12] in 2010 had not found any association between the parameters cited above and EFV plasma concentrations (R 2 = 0.107). Our observations are also in agreement with results obtained by Kappelhoff et al. [10] , who did not find any association between weight, BMI and EFV plasma concentrations. However, divergent data exist in the literature. Stohr et al. had found that a high weight induced a weak plasmatic concentration of EFV [5] . Brazilian study of Poeta et al. [15] in 2011 had also revealed that high BMI induced weak level concentration of EFV (p = 0.001) [15] . Also, high BMI can mean a great drug distribution volume and thus, low plasma concentration. This difference with our result could be explained by the fact that the population Poeta et al. studied was slightly in overweight (25.6 kg/m 2 against 22.6 kg/m² in our study). A more recent study has shown the absence of relationship between demographic characteristics or biochemical parameters and EFV concentrations using a pharmacokinetic model developed from 96 included patients [17] . This study suggests that polymorphism of CYP2B6 was the only covariates that could influence pharmacokinetic parameters of EFV.
Plasma Concentrations and Therapeutic Regimen
Three types of therapeutic regimens were used by our patients (Table 1 ). All therapeutic regimens have in common lamivudine and EFV. We did not observe significant difference between medians of EFV plasma concentrations among various therapeutic regimens. This indicates that neither TDF, d4T, nor AZT seems to impact significantly EFV metabolism or its distribution. Concerning the distribution of EFV concentrations in the therapeutic margin described (under therapeutic, therapeutic, supratherapeutic), there is not any difference between various regimes of our study opposite to results found by Gunda et al. [14] . Indeed, stavudine and lamivudine induced plasma concentrations of NNRTI below the therapeutic index. On the other hand, zidovudine and lamivudine associated with NNRTI drugs could cause an increase of NNRTI plasma concentration. Tenofovir and emtricitabine allowed obtaining plasma concentration included in the therapeutic margin [18] .
Adverse Effects
About 87% of our study population presented adverse effects on CNS. Similar frequencies have been reported by several authors [13, 19, 20] . However, within the framework of a study carried out in Ghana in 2013, only 9.4 % of HIV-infected patients had presented AE on CNS [13] . All studies undertaken on efavirenz confirmed that it's responsible for neurosensory AE. From the results presented in Table 2 , dizzinesses were most dominating. Frequency of dizzinesses found in our study is significant compared with those brought back by Gounden et al., Diop et al., and Fumaz et al. [12, 18, 21] . Moreover, a study carried out in Benin on undesirable effect of antiretroviral drugs in 130 HIV-infected patients, argues the high frequency (64.6%) of neuropsychic effects when using ART based on EFV [20] .
In our study, we did not inventoried psychic affections such as anxiety, severe depression, ideas of suicide, aggressive behaviors, maniacs and paranoiac reactions. In the same way, Vrouenraets et al. [22] did not report these affections. In contrast, it has been reported cases of patients suffering from depression (17%) and delirium (13%) in other study [23] . Absence of identification of certain psychiatric AE in our study can be related to skews of questionnaire used during the data-gathering. Indeed, the patients could not appreciate themselves the nature of psychiatric effects. Moreover, the transverse nature of our study was not favorable to collect chronic psychiatric affections.
In short, AE on CNS are most relevant and documented. In 2014, several studies reported that EFV AE on CNS occurred in more than half of patients [24] . However, prevalence of this toxicity is variable because of the contradictory definition and detection method used to appreciate "CNS toxicity" [14] .
In addition to neuropsychic effects, we highlighted gastro-intestinal, cutaneous and general effects in proportion of 31.2%, 36.6% and 44.6%, respectively.
Plasma Concentrations and Adverse Effects
We investigated if presence of certain AE were related to a high EFV level, in particular a concentration higher than 4000 µg/L. In any cases, subjects exhibiting supratherapeutic concentration significantly did not present any more risk to feel particular AE. As surprising as that could be, patients in our study had in general very high plasma concentrations of EFV. Opposite to several authors who have found association between EFV plasma concentration and presence of neuropsychic AE [1, 5, [25] [26] [27] [28] , we did not highlighted such an association in our study. This could be related to the transverse nature of our study involving under-notification. In addition, it has been argued that neuropsychic AE induced by EFV were light and patients' capacity to support them settled at the end of couple weeks, especially subjects having defective genotypes CYP2B6 and exhibiting high plasma levels [29] . It is most likely case of many patients of our study. Assumption according to which patient educated to AE improve their tolerance degree towards these AE is also plausible.
However, we observed a significant correlation between the number of AE and plasma concentration. This result could reinforce recommendation of daily dose reduction for patients who exhibiting supratherapeutic concentration without affecting viral charge suppression. Patients having high plasma concentration of EFV should be subjected to closely follow-up. A recent study has shown that once-daily EFV 400 mg dose was so effective than once-daily EFV 600 mg despite lower plasma concentrations obtained, even if this study was probably critical because it compared pharmacokinetic parameters and plasma concentrations obtained at week 4 or 8 and clinical outcome at week 96 [30] . This study included 606 patients with 37% of African and 33% of Asian people.
In our study, only 2.7 % of the patients exhibited plasma concentration below the therapeutic margin. Within sight of these results, we can suppose high frequency of CYP2B6 516GT, CYP2B6 516TT and 983CT alleles in our study, thus explaining the strong plasma concentrations of EFV (46.4% of the patients above 4,000 ng/mL). In fact, EFV plasma concentrations are characterized by interindividual variance which is explained partly by CYP2B6 polymorphisms [17, 19] . Alleles 516GT, 516TT and 983CT are defective, inducing a slow metabolism of EFV and consequently high plasma concentrations. Siccardi et al. in 2012 had carried out a model of extrapolation concluding that it was necessary to reduce by 200 mg dose of EFV among patients having 516GT mutation, and by 400 mg for those having 516TT mutation of CYP2B6 gene [29] . Unfortunately, we were not able to determine CYP2B6 or CYP3A4 polymorphism gene of patients because of limited technical plate for genetic tests. CYP2B6 genotype of patients could provide data even more convincing to improve patients care.
To our knowledge, our study is the first report of such over-exposure to plasma concentrations among Beninese population of HIV patients treated by a 600 mg daily dose of EFV. In 322 Chinese patients, Meng et al. have shown that with a 600 mg daily dose of EFV, average EFV plasma concentration was 2,350 ± 2,090 µg/L, with 13.1% presenting concentration below 1,000 µg/mL and only 9.3% with concentrations above 4,000 µg/mL [31] . High concentrations were associated with polymorphisms of CYP2B6.
Conclusions
Our study highlighted an over-exposure to EFV drug 
